⚠ The Growth Is Concentrating Where the Case Is WeakestHigh threat
Intuitive Surgical (ISRG) — threat to the moat
The fastest-growing categories have the smallest clinical edge, the same instrument cost, and the highest sensitivity to insurance.
Intuitive's procedure mix has moved a long way from where the franchise started, and the direction is toward less defensible ground.
In the United States, general surgery is 1,250,000 of 2,012,000 procedures — about 62% — against 201,000 in urology1. Urology is where robotic assistance is most clearly superior and where conversion is largely complete; it grew 8% in 2025. General surgery grew 18%, led by cholecystectomy, hernia repair and appendectomy2.
The problem is that those are exactly the operations where laparoscopy is mature, fast and cheap. Intuitive says so twice in its own filing: on cholecystectomy, "given the already very high level of laparoscopic techniques used in cholecystectomy procedures, it remains unclear to what extent robotic-assisted surgery using da Vinci may continue to be adopted"; on appendectomy, "similar to cholecystectomy procedures, there is currently a high level of laparoscopic techniques used"3. On hernia repair it adds that "we expect a large portion of hernia repairs will continue to be performed via different modalities of surgery."
These are also the most deferrable procedures in the book, which is why they softened first when insurance coverage changed4. So the fastest-growing part of the mix is simultaneously the part with the weakest clinical differentiation, the largest cost gap against the alternative, and the highest sensitivity to whether a patient is insured.
The series to watch is United States general surgery growth against urology. Both decelerating is a demand problem. General surgery decelerating while urology holds is an argument problem, and the second is harder to fix.
- Moat Explorer calcIn the United States, general surgery is 1,250,000 of 2,012,000 procedures — about 62% — against 201,000 in urology.Moat Explorer calculation - arithmetic on figures reported in Intuitive's Form 10-K and Form 10-Q: instruments and accessories of $6,018.9M over 3,153,000 da Vinci plus 144,100 Ion procedures ($1,825 a procedure), service revenue of $1,572.1M over the installed base (about $134,000 a system), variable lease revenue of $531M over 1,810 usage-based systems (about $293,000), procedures over the average installed base (about 300 a system), each revenue line as a share of the $10,064.7M total, and US general surgery as a share of US procedures — FY2025 · publ. September 2026 · source ↗
- ReportedGeneral surgery grew 18%, led by cholecystectomy, hernia repair and appendectomy.Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, business and operating highlights (3,153,000 da Vinci procedures up 18%, 1,721 placements, an installed base of 11,106, utilisation up about 3%, 870 da Vinci 5 placements, Ion procedures and placements, procedures by region and category, and revenue denominated in foreign currencies) — FY2025 · publ. February 3, 2026 · source ↗
- Reportedit remains unclear to what extent robotic-assisted surgery using da Vinci may continue to be adopted"; on appendectomy, "similar to cholecystectomy procedures, there is currently a high level of laparoscopic techniques used".Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗
- ReportedOn hernia repair it adds that "we expect a large portion of hernia repairs will continue to be performed via different modalities of surgery." These are also the most deferrable procedures in the book, which is why they softened first when...Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗